AR044207A1 - Compuestos de benzopirano utiles para tratar estados inflamatorios - Google Patents

Compuestos de benzopirano utiles para tratar estados inflamatorios

Info

Publication number
AR044207A1
AR044207A1 ARP040101056A ARP040101056A AR044207A1 AR 044207 A1 AR044207 A1 AR 044207A1 AR P040101056 A ARP040101056 A AR P040101056A AR P040101056 A ARP040101056 A AR P040101056A AR 044207 A1 AR044207 A1 AR 044207A1
Authority
AR
Argentina
Prior art keywords
group
compounds
arylalkyl
alkyl
benzopirane
Prior art date
Application number
ARP040101056A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR044207A1 publication Critical patent/AR044207A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se refiere a métodos y compuestos que tienen utilidad en el tratamiento de una afección asociada con trastornos mediados por la cicloxigenasa-2. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en la que: X se selecciona entre el grupo compuesto por H, alquilo y un catión farmacéuticamente aceptable; Z se selecciona entre el grupo compuesto por O, S y NH; donde cada uno de R1, R2 R3 y R4 se seleccionan independientemente entre el grupo compuesto por H, alquenilo, alcoxi, alcoxialquilo, alcoxicarbonilalquilo, alquilo, alquilamino, alquilcarbonilo, alquilheteroarilo, alquilsulfonilalquilo, alquiltio, alquinilo, aminocarbonilalquilo, arilo, arilalquenilo, arilalcoxi, arilalquilo, arilalquilamino, arilalquinilo, arilcarbonilo, ariloxi, ciano, dialquilamino, halo, haloalcoxi, haloalquilo, heteroarilo, heteroarilalcoxi, heteroarilcarbonilo, hidroxi e hidroxialquilo; donde cada uno de los arilos, dondequiera que se encuentren, está independientemente sustituido con uno a cinco sustituyentes seleccionados entre el grupo compuesto por alquilo, alcoxi, alquilamino, ciano, halo, haloalquilo, hidroxi y nitro.
ARP040101056A 2003-03-31 2004-03-30 Compuestos de benzopirano utiles para tratar estados inflamatorios AR044207A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45921503P 2003-03-31 2003-03-31

Publications (1)

Publication Number Publication Date
AR044207A1 true AR044207A1 (es) 2005-09-07

Family

ID=33131871

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101056A AR044207A1 (es) 2003-03-31 2004-03-30 Compuestos de benzopirano utiles para tratar estados inflamatorios

Country Status (25)

Country Link
US (1) US7259266B2 (es)
EP (1) EP1615905A2 (es)
JP (1) JP2006522098A (es)
KR (1) KR20060015490A (es)
CN (1) CN1768050A (es)
AR (1) AR044207A1 (es)
AU (1) AU2004226164A1 (es)
BR (1) BRPI0408388A (es)
CA (1) CA2520724A1 (es)
EA (1) EA200501399A1 (es)
EC (2) ECSP056063A (es)
IS (1) IS7995A (es)
MA (1) MA27725A1 (es)
MX (1) MXPA05010630A (es)
NL (9) NL1025843C2 (es)
NO (1) NO20054121L (es)
OA (1) OA13112A (es)
PA (1) PA8599601A1 (es)
PE (1) PE20050012A1 (es)
RS (1) RS20050744A (es)
TN (1) TNSN05249A1 (es)
TW (1) TWI257927B (es)
UY (1) UY28252A1 (es)
WO (1) WO2004087686A2 (es)
ZA (1) ZA200506551B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
WO2006011052A1 (en) * 2004-07-23 2006-02-02 Pharmacia & Upjohn Company Llc Method for the racemization of 2-trifluoro-2h-chromene-3-carboxylic acids
BRPI0512251A (pt) * 2004-07-23 2008-02-19 Pharmacia & Upjohn Co Llc método enantioseletivo para separação de derivados do ácido 2-trifluormetil-2h-cromeno-3-carboxìlico substituìdo
JP2008507501A (ja) * 2004-07-23 2008-03-13 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−トリフルオロメチル−２ｈ−クロメン−３−カルボン酸誘導体の光ラセミ化
EP1792887A1 (en) * 2005-12-05 2007-06-06 Laboratorios Del Dr. Esteve, S.A. Process for the homogeneous hydrogenation of ketones using ruthenium catalytic systems
EP2234486A4 (en) * 2007-12-19 2011-09-14 Scripps Research Inst BENZIMIDAZOLE AND ANALOGUE AS RHO-KINASEHEMMER
CA2709918A1 (en) * 2007-12-21 2009-06-25 The Scripps Research Institute Benzopyrans and analogs as rho kinase inhibitors
US20110038835A1 (en) * 2007-12-21 2011-02-17 The Scripps Research Institute Anilides and analogs as rho kinase inhibitors
CN102757417B (zh) * 2012-06-18 2014-09-24 中国科学院广州生物医药与健康研究院 氘代苯并吡喃类化合物及其应用
CN103012350B (zh) * 2012-12-07 2015-02-04 中国科学院广州生物医药与健康研究院 苯并吡喃类手性化合物的合成方法
EP2860177A3 (en) * 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
WO2015047113A1 (en) * 2013-09-30 2015-04-02 Polfarmex S.A. Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as η1-receptor antagonists
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
CN106102747A (zh) * 2014-01-14 2016-11-09 欧利瑟斯制药公司 释放no的硝基氧基‑色烯结合物
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
CN107868069A (zh) * 2017-10-31 2018-04-03 山东新华制药股份有限公司 7‑羟基‑8‑甲基‑6‑硝基‑2‑氧‑2h‑苯并吡喃‑3‑羧酸的制备工艺
EP3787543A4 (en) 2018-05-02 2022-01-19 Augmedics Ltd. REGISTRATION OF A REFERENCE MARK FOR AN AUGMENTED REALITY SYSTEM
CN109020990A (zh) * 2018-09-20 2018-12-18 广西壮族自治区药用植物园 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
WO2023012081A1 (en) 2021-08-05 2023-02-09 Syngenta Crop Protection Ag Method for controlling diamide resistant pests & compounds therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794734A (en) 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US20030153801A1 (en) 2001-05-29 2003-08-14 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
US6620871B2 (en) * 2001-06-07 2003-09-16 Nike, Inc. Rubber compositions with increased shelf life and reduced cure temperatures and times
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor

Also Published As

Publication number Publication date
CN1768050A (zh) 2006-05-03
WO2004087686A3 (en) 2004-12-16
ZA200506551B (en) 2006-11-29
US7259266B2 (en) 2007-08-21
NL1028303A1 (nl) 2005-03-09
NL1028305A1 (nl) 2005-03-09
MXPA05010630A (es) 2005-12-12
EP1615905A2 (en) 2006-01-18
KR20060015490A (ko) 2006-02-17
NL1028303C2 (nl) 2005-11-16
TW200510365A (en) 2005-03-16
IS7995A (is) 2005-08-18
NL1028304C2 (nl) 2005-11-16
OA13112A (en) 2006-11-10
NL1028304A1 (nl) 2005-03-09
NL1028308A1 (nl) 2005-03-09
RS20050744A (en) 2007-08-03
TWI257927B (en) 2006-07-11
MA27725A1 (fr) 2006-01-02
PA8599601A1 (es) 2005-05-24
WO2004087686A2 (en) 2004-10-14
CA2520724A1 (en) 2004-10-14
NL1028307A1 (nl) 2005-03-09
NL1025843A1 (nl) 2004-10-01
UY28252A1 (es) 2004-11-08
NL1028310C2 (nl) 2005-11-16
US20050148777A1 (en) 2005-07-07
ECSP056063A (es) 2006-01-27
NL1028309A1 (nl) 2005-03-09
PE20050012A1 (es) 2005-03-12
JP2006522098A (ja) 2006-09-28
NL1028309C2 (nl) 2005-11-16
NL1028308C2 (nl) 2005-11-16
NL1028307C2 (nl) 2005-11-16
NL1028305C2 (nl) 2005-11-16
NL1028310A1 (nl) 2005-03-09
TNSN05249A1 (fr) 2007-06-11
NL1025843C2 (nl) 2005-03-01
NO20054121D0 (no) 2005-09-05
ECSP056064A (es) 2006-01-27
NL1028306C2 (nl) 2005-11-16
EA200501399A1 (ru) 2006-04-28
AU2004226164A1 (en) 2004-10-14
BRPI0408388A (pt) 2006-03-01
NO20054121L (no) 2005-12-20
NL1028306A1 (nl) 2005-03-09

Similar Documents

Publication Publication Date Title
AR044207A1 (es) Compuestos de benzopirano utiles para tratar estados inflamatorios
RU2440991C2 (ru) Хиназолины, полезные в качестве модуляторов ионных каналов
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
DK3889142T3 (da) 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsense-suppression og behandling af sygdom
TW200615264A (en) N-(ortho-phenyl)-1-methyl-3-difluoromethylpyrazole-4-carboxanilides and their use as fungicides
NO20062894L (no) 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer
AR053834A1 (es) Compuestos de 2- cianobencenosulfonamida para el tratamiento de semillas
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
CO6260136A2 (es) Metodo para preparar derivados de 5-haloalquil-4,5-dihidroisoxazol
NO20021379L (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
EA200802329A1 (ru) Производные триазола ii
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
NO20050738L (no) Ny fremgangsmate for syntesen av (7-metoksy-3,4-dihydro-1-naftalanyl)acetonitril og dens anvendelse i syntesen av agomelatin
NO20062453L (no) Tiozolidinoner, fremstilling og anvendelse derav som legemidler
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
CY1111596T1 (el) Υποκατεστημενες ακετοφαινονες χρησιμες ως αναστολεις pde4
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
AR057566A1 (es) 2- acilaminotiazol -4- carboxamidas insecticidas
DK1853232T3 (da) Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
AR065249A1 (es) Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales.
RS54737B1 (sr) Derivati benzazola kao veznici h4 receptora histamina

Legal Events

Date Code Title Description
FB Suspension of granting procedure